<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942025000400412</article-id>
<article-id pub-id-type="doi">10.30827/ars.v66i4.33508</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Refining the Performance of Abiraterone Acetate through Industry-friendly Techniques for Improving Functionality]]></article-title>
<article-title xml:lang="es"><![CDATA[Refinando el rendimiento del acetato de abiraterona mediante técnicas industriales para mejorar la funcionalidad]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[Hardik]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Khambholja]]></surname>
<given-names><![CDATA[Vraj]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[Vaishali]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gadhvi]]></surname>
<given-names><![CDATA[Varsha]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rabari]]></surname>
<given-names><![CDATA[Prachi]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[Tejal]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Anand Pharmacy College Department of Pharmaceutics ]]></institution>
<addr-line><![CDATA[Anand Gujarat]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>66</volume>
<numero>4</numero>
<fpage>412</fpage>
<lpage>425</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942025000400412&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942025000400412&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942025000400412&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Introduction: Main objective of this study was to enhance solubility and permeability of Abiraterone Acetate (AA) by industry-feasible techniques. Method: Solid dispersion (SD) of Abiraterone with Gelucire 44/14 (GC44/14), Dexolve, and Eudragit EPO were prepared using various functionality-improving techniques. These properties were characterized by phase solubility, dissolution, permeability, flow properties, differential scanning calorimetry, Fourier transform Infrared Spectroscopy, and X-ray diffraction. Among various techniques and polymers, spray drying with Gelucire was selected based on its ability to enhance solubility. A 32 full factorial design was applied to optimize SD, focusing on dissolution, solubility, and flow property (angle of repose), with material attributes being Abiraterone: Gelucire ratio and Neusilin (NS) amount. Optimal region was selected from overlay plot. Results: Spray-dried SD exhibited highest solubility, which increased with Gelucire at a 1:2 ratio, resulting in a 405.94-fold increase in solubility. DSC, FTIR, and XRD showed Abiraterone transformation from crystalline to amorphous. Nine batches showed a drug release ranging from 30.85% to 90.33 % at 30 minutes, with solubility between 141.049 &#956;g/mL and 286.307 &#956;g/mL. Angle of repose ranged from fair to excellent. Optimized batch exhibited 85.51% drug release at 30 min, a solubility of 282.296 &#956;g/mL, and good flow. Ex vivo permeability studies revealed 9.32 ± 0.147 % for Abiraterone and 51.72 ± 0.286 % for optimal batch at 90 min. Conclusion: Solubility, permeability, and dissolution increased significantly when a SD of Abiraterone was prepared with Abiraterone and Neusilin by spray drying method. Systematic, industry-friendly techniques will benefit patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Introducción: El objetivo principal de este estudio fue mejorar la solubilidad y la permeabilidad del acetato de abiraterona mediante técnicas industrialmente viables. Método: Se prepararon dispersiones sólidas de abiraterona con Gelucire 44/14, Dexolve y Eudragit EPO mediante diversas técnicas de mejora de la funcionalidad. Estas se caracterizaron por la solubilidad de fase, la disolución, la permeabilidad y las propiedades de flujo, mediante calorimetría diferencial de barrido, Espectroscopia Infrarroja por Transformada de Fourier y difracción de rayos X. Entre las técnicas y polímeros, se seleccionó el secado por aspersión con Gelucire debido a su mejora en la solubilidad. Se aplicó un diseño factorial completo de 32 para optimizar la dispersión sólida, centrándose en la disolución, la solubilidad y las propiedades de flujo (ángulo de reposo), siendo los atributos del material la relación abiraterona: Gelucire y la cantidad de neusilina. La región óptima se seleccionó a partir del gráfico de superposición. Resultados: La dispersión sólida secada por aspersión mostró el mayor aumento de solubilidad con Gelucire en una proporción de 1:2, alcanzando un incremento de 405,94 veces. Los análisis mediante calorimetría diferencial de barrido, Espectroscopia Infrarroja por Transformada de Fourier y difracción de rayos X mostraron la transformación de la abiraterona de cristalino a amorfo. Los nueve lotes mostraron un %CDR que osciló entre el 30,85 % y el 90,33 % a los 30 minutos, con una solubilidad entre 141,049 &#956;g/mL y 286,307 &#956;g/mL. Las propiedades de flujo variaron de regulares a excelentes. El lote optimizado mostró una liberación del fármaco del 85,51 % a los 30 min, una solubilidad de 282,296 &#956;g/mL y un buen flujo. Los estudios de permeabilidad ex vivo revelaron un 9,32 ± 0,147 % para la abiraterona y un 51,72 ± 0,286 %para el lote óptimo a los 90 min. Conclusión: La solubilidad, la permeabilidad y la disolución aumentaron significativamente al preparar una dispersión sólida de abiraterona con Gelucire y neusilina mediante el método de secado por aspersión. Esta técnica sistemática y de fácil aplicación en la industria beneficiará al paciente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Abiraterona]]></kwd>
<kwd lng="es"><![CDATA[mejora de la funcionalidad]]></kwd>
<kwd lng="es"><![CDATA[Neusilina]]></kwd>
<kwd lng="es"><![CDATA[secado por aspersión]]></kwd>
<kwd lng="es"><![CDATA[Gelucire]]></kwd>
<kwd lng="en"><![CDATA[Abiraterone]]></kwd>
<kwd lng="en"><![CDATA[functionality improvement]]></kwd>
<kwd lng="en"><![CDATA[Neusilin]]></kwd>
<kwd lng="en"><![CDATA[spray drying]]></kwd>
<kwd lng="en"><![CDATA[Gelucire]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sankarapillai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ramamoorthy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sudarshan]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Mathur]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descriptive epidemiology of prostate cancer in India , 2012 - 2019 : Insights from the National Cancer Registry Programme]]></article-title>
<source><![CDATA[Indian J Urol]]></source>
<year>2024</year>
<volume>40</volume>
<page-range>167-73</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Laversanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality : An Update]]></article-title>
<source><![CDATA[Eur Urol.]]></source>
<year>2024</year>
<volume>87</volume>
<page-range>302-13</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rebecca]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Mph]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2024</year>
<volume>74</volume>
<page-range>229-63</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beg]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Ansari]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[AMA]]></given-names>
</name>
<name>
<surname><![CDATA[Theyab]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic Development of Solid Lipid Nanoparticles of Abiraterone Acetate with Improved Oral Bioavailability and Anticancer Activity for Prostate Carcinoma Treatment]]></article-title>
<source><![CDATA[ACS Omega]]></source>
<year>2022</year>
<volume>7</volume>
<page-range>16968-79</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fiala]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Hosek]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Korunkova]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hora]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kolar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Windrichova]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2023</year>
<volume>43</volume>
<page-range>463-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yanagisawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kimura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Otsuka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2022</year>
<volume>82</volume>
<page-range>3-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oyman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ba&#351;ak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Özçelik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Özyükseler]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[I&#351;&#305;k]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Y&#305;ld&#305;r&#305;m]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis]]></article-title>
<source><![CDATA[Asia Pac J Clin Oncol]]></source>
<year>2021</year>
<volume>17</volume>
<page-range>e201-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danielak]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Krej&#269;í]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Beránek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products]]></article-title>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2022</year>
<volume>176</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malik]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Momin]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Shaikh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alafnan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alanazi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug Repurposing: A New Hope in Drug Discovery for Prostate Cancer]]></article-title>
<source><![CDATA[ACS Omega]]></source>
<year>2023</year>
<volume>8</volume>
<page-range>56-73</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solymosi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tóth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orosz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Basa-Dénes]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Angi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jordán]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate]]></article-title>
<source><![CDATA[J Chem Eng Data]]></source>
<year>2018</year>
<volume>63</volume>
<page-range>4453-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katekar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Riyazuddin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Husain]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Augmented experimental design for bioavailability enhancement: a robust formulation of abiraterone acetate]]></article-title>
<source><![CDATA[J Liposome Res]]></source>
<year>2023</year>
<volume>33</volume>
<page-range>65-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Meola]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Prestidge]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2020</year>
<volume>577</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<source><![CDATA[Development of a resveratrol solid dispersion with enhanced oral bioavailability by the lyophilization method]]></source>
<year>2024</year>
<publisher-name><![CDATA[ICBAS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pyo]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>1-26</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ha]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Baek]]></surname>
<given-names><![CDATA[IH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced oral bioavailability of resveratrol by using neutralized eudragit e solid dispersion prepared via spray drying]]></article-title>
<source><![CDATA[Antioxidants]]></source>
<year>2021</year>
<volume>10</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choudhari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Damle]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saha]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Dubey]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Singhvi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulating abiraterone acetate-HPMCAS-based amorphous solid dispersions: insights into in vitro and biorelevant dissolution assessments and pharmacokinetic evaluations]]></article-title>
<source><![CDATA[RSC Adv]]></source>
<year>2024</year>
<volume>14</volume>
<page-range>38492-505</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malkawi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Malkawi]]></surname>
<given-names><![CDATA[WI]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Mahmoud]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tawalbeh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current Trends on Solid Dispersions: Past, Present, and Future]]></article-title>
<source><![CDATA[Adv Pharmacol Pharm Sci]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagh]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
<name>
<surname><![CDATA[Gilhotra]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Wagh]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid dispersion (Kneading) technique: A platform for enhancement dissolution rate of valsartan poorly water soluble drug]]></article-title>
<source><![CDATA[Int J Pharm Qual Assur]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>20-4</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nazir]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chauhdary]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Irfan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khalid]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Asghar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhanced Solubility and Biological Activity of Dexibuprofen-Loaded Silica-Based Ternary Solid Dispersions]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2023</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Saadia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naeem-Ul-Hassan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rehman]]></surname>
<given-names><![CDATA[MF ur]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical and Pharmacological Evaluation of Amoxicillin after Solubility Enhancement Using the Spray Drying Technique]]></article-title>
<source><![CDATA[ACS Omega]]></source>
<year>2022</year>
<volume>7</volume>
<page-range>48506-19</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the development of amorphous solid dispersions: The role of polymeric carriers]]></article-title>
<source><![CDATA[Asian J Pharm Sci]]></source>
<year>2023</year>
<volume>18</volume>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chhajed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dwivedi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved Dissolution and Solubility Characteristics of Clopidogrel Bisulphate using Gelucire 44/14]]></article-title>
<source><![CDATA[Eur J Parenter Pharm Sci]]></source>
<year>2024</year>
<volume>29</volume>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Irfan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lali]]></surname>
<given-names><![CDATA[NUA]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Asghar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[IU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and Characterization of Eudragit® EPO-Based Solid Dispersion of Rosuvastatin Calcium to Foresee the Impact on Solubility, Dissolution and Antihyperlipidemic Activity]]></article-title>
<source><![CDATA[Pharmaceuticals]]></source>
<year>2022</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvalho Feitosa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Souza Ribeiro Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van Vliet Lima]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sawa Akioka Ishikawa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cogo Müller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bonin Okasaki]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supramolecular Arrangement of Doxycycline with Sulfobutylether-&#946;-Cyclodextrin: Impact on Nanostructuration with Chitosan, Drug Degradation and Antimicrobial Potency]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2023</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of Polymers on the Drug Solubility and Dissolution Enhancement of Poorly Water-Soluble Rivaroxaban]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2022</year>
<volume>23</volume>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maulvi]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Dalwadi]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
<name>
<surname><![CDATA[Soni]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Gohel]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement of dissolution rate of aceclofenac by solid dispersion technique]]></article-title>
<source><![CDATA[Powder Technol]]></source>
<year>2011</year>
<volume>207</volume>
<page-range>47-54</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanojiya]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Charde]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Avari]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Wadetwa]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solid Dispersion of Lumefantrine Using Soluplus® by Solvent Evaporation Method: Formulation, Characterization and in-vitro Antimalarial Screening]]></article-title>
<source><![CDATA[Indian J Pharm Educ Res]]></source>
<year>2022</year>
<volume>56</volume>
<page-range>121-32</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buya]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Mahlangu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Witika]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[From lab to industrial development of lipid nanocarriers using quality by design approach]]></article-title>
<source><![CDATA[Int J Pharm X]]></source>
<year>2024</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gude]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Solubility enhancement and quality by design (qbd) assisted fabrication of fast dissolving buccal film for risperidone]]></article-title>
<source><![CDATA[IJPSR]]></source>
<year>2023</year>
<volume>14</volume>
<page-range>459-81</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wathore]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Chhajed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[To Design QBD ( Quality-by-Design ) Approach to Understand the Processing Factors Impact Melt-Extruded Solid Dispersions with an Instantaneous Release]]></article-title>
<source><![CDATA[Int J Pharm Biol Sci Arch]]></source>
<year>2024</year>
<volume>12</volume>
<page-range>109-18</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2022</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahoud]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abdlwahed]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hammad]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development a taste-masked acetaminophen solid dispersions using Eudragit® E100 polymer by solvent evaporation technique]]></article-title>
<source><![CDATA[J Res Pharm]]></source>
<year>2023</year>
<volume>27</volume>
<page-range>1998-2006</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inclusion complex of lurasidone hydrochloride with Sulfobutylether-&#946;-cyclodextrin has enhanced oral bioavailability and no food effect]]></article-title>
<source><![CDATA[Am J Transl Res]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>1495-506</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Di]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation of curcumin-eudragit® EPO solid dispersions with gradient temperature through Hot-Melt extrusion]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2021</year>
<volume>26</volume>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Rathkopf]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Efstathiou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Attard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Olmos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2023</year>
<volume>41</volume>
<page-range>3339-51</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fouad]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Malaak]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[El-Nabarawi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Zeid]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Ghoneim]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation of solid dispersion systems for enhanced dissolution of poorly water soluble diacerein: In-vitro evaluation, optimization and physiologically based pharmacokinetic modeling]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2021</year>
<volume>16</volume>
<page-range>1-26</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sitovs]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mohylyuk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ex vivo permeability study of poorly soluble drugs across gastrointestinal membranes: acceptor compartment media composition]]></article-title>
<source><![CDATA[Drug Discov Today]]></source>
<year>2024</year>
<volume>29</volume>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Penman]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Manton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fioravanzo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Powrie]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the Intestinal Absorption of Higher Olefins by the Everted Gut Sac Model in Combination with in Silico New Approach Methodologies]]></article-title>
<source><![CDATA[Chem Res Toxicol]]></source>
<year>2022</year>
<volume>35</volume>
<page-range>1383-92</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polymer selection for amorphous solid dispersion of a new drug candidate by investigation of drug polymer molecular interactions]]></article-title>
<source><![CDATA[Pharmazie]]></source>
<year>2023</year>
<volume>78</volume>
<page-range>185-95</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bukkapatnam]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Mukthinuthalapati]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Routhu]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study on Stress Degradation Behaviour of Abiraterone Acetate in Film Coated Tablets and Identification of Major Stress Degradation Product by Liquid Chromatography-Ultraviolet-Electrospray Ionization-Mass Spectrometry]]></article-title>
<source><![CDATA[Indian J Pharm Sci]]></source>
<year>2022</year>
<volume>84</volume>
<page-range>300-10</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gala]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved dissolution and pharmacokinetics of abiraterone through kinetisol® enabled amorphous solid dispersions]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enhancement of Dissolution Rate of Valdecoxib Using Solid Dispersions with Polyethylene Glycol 4000]]></article-title>
<source><![CDATA[Drug Dev Ind Pharm]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wadher]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Umekar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lohiya]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation, Optimization and Evaluation of Solid Dispersion of Deferasirox Using Factorial Design]]></article-title>
<source><![CDATA[J Drug Deliv Ther]]></source>
<year>2024</year>
<volume>14</volume>
<page-range>23-31</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertoni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Albertini]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Passerini]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of polyoxylglycerides-based excipients (Gelucire®) on ketoprofen amorphous solubility and crystallization from the supersaturated state]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2025</year>
<volume>669</volume>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamizhmathy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Shettiwar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shiva]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Formulation of inclusion complex of Abiraterone acetate with 2-Hydroxy propyl-Beta-Cyclodextrin : physiochemical characterization , molecular docking and bioavailability evaluation]]></article-title>
<source><![CDATA[Journal of Drug Delivery Science and Technology]]></source>
<year>2023</year>
<volume>82</volume>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bakhrushina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Buraya]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Moiseev]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Shumkova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Davydova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Krasnyuk]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing Abiraterone Delivery through Intratumoral In Situ Implant: A Prospective Pharmaceutical Development Approach]]></article-title>
<source><![CDATA[Sci Pharm]]></source>
<year>2023</year>
<volume>2</volume>
<page-range>37-45</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braeckmans]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Augustijns]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mols]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Servais]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2022</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Møller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Meola]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations]]></article-title>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2021</year>
<volume>157</volume>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mondal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sirvi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jadhav]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sangamwar]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supersaturating lipid-based solid dispersion of atazanavir provides enhanced solubilization and supersaturation in the digestive aqueous phase]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2023</year>
<volume>638</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dholakia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gohel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demonstration of Advanced Data Mining Tools for Optimization of Pellets Employing Modified Extrusion-pelletization Technique]]></article-title>
<source><![CDATA[Curr Drug Ther]]></source>
<year>2020</year>
<volume>16</volume>
<page-range>154-69</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Gohel]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Dholakia]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Omri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of Sustained Release Pellets of Galantamine HBr by Extrusion Spheronization Technique Incorporating Risk based QbD Approach]]></article-title>
<source><![CDATA[Res J Pharm Technol]]></source>
<year>2018</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Panchal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dholakia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigating in-vitro functionality and in-vivo taste assessment of eco-friendly Tadalafil Pastilles]]></article-title>
<source><![CDATA[Heliyon]]></source>
<year>2024</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thakkar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atovaquone smart lipid system: Design, statistical optimization, and in-vitro evaluation]]></article-title>
<source><![CDATA[Food Hydrocoll Heal]]></source>
<year>2023</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benmore]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Benmore]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Shrader]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Bhat]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A high energy x-ray diffraction study of amorphous Indomethacin]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>2022</year>
<volume>111</volume>
<page-range>818-24</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
